Henry Schein

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial on a non-recourse basis, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Henry Schein reports solid Q4 performance and anticipates growth

Henry Schein's Q4 performance showcased growth amidst challenges, with a strategic focus on core margin expansion and strong performance in dental specialties. While facing challenges from declining PPE sales and supply chain issues, the company sees opportunities in stable dental markets and continued growth in operating income. Overall, the company remains optimistic about its outlook for 2023.

Henry Schein reports strong Q1 earnings, eyes growth through acquisitions

Henry Schein's Q1 2023 earnings call highlighted strong financial performance across its dental, medical, and Technology and Value-Added Services businesses. While facing challenges from declining PPE and COVID-19 test kit sales, the company remains optimistic about growth opportunities through acquisitions and stable business segments.

Henry Schein reports solid Q2 results, eyes growth opportunities

Henry Schein's Q2 performance was driven by strong dental sales, while facing challenges from declining PPE and COVID test kit sales. The company is focused on strategic acquisitions and expanding product offerings, with opportunities in technology and specialty products driving growth.

Henry Schein navigates post-cyber incident challenges, focuses on recovery

Henry Schein faced challenges from a cybersecurity incident impacting operations but showcased resilience and recovery efforts across its business segments.
Strategic initiatives focused on customer retention, operational efficiency, and cybersecurity response highlight the company's commitment to long-term growth and stability.
Despite challenges in specific segments and cybersecurity spending variables, Henry Schein's focus on recovery, cost-cutting, and customer trust positions it for future opportunities.
The company's emphasis on digital channels, stable medical demand, and strategic cost-cutting measures underscores its adaptability and strategic vision for sustained growth.

Henry Schein reports resilient Q4 performance and outlines 2024 guidance

Henry Schein's Q4 2023 performance reflects resilience amidst challenges, with a strategic focus on technology, global sales, and recovery post-cyber incident. The company's 2024 outlook includes managing residual cyber impacts and pursuing growth opportunities.

Henry Schein reports solid Q1 earnings, eyes market share expansion

Henry Schein's Q1 performance reflects resilience and growth across key segments, with a focus on market share expansion and profitability. While facing challenges in dental consumables and pricing stability, the company is leveraging opportunities in product portfolio expansion and market positioning. Strategic acquisitions and recovery efforts post-cyber incident are driving competitive strength and customer loyalty.

Henry Schein reports mixed Q2 performance, focuses on cost savings

Henry Schein navigated challenges from a cyber incident, with mixed performance across segments in Q2 2024.
Strong sales growth in dental specialties, focus on cost savings, and resilience in technology services were highlights.
The company's strategic initiatives, financial guidance update, and confidence in future prospects were key takeaways from the call.

Henry Schein excels in Q3 with strategic growth initiatives

Henry Schein's Q3 performance reflects strong market positioning and strategic execution, driving growth across key business segments.
While facing challenges such as LCI sales decline, the company's focus on operational efficiency and cost management remains a priority.
With increased sales guidance, ongoing restructuring initiatives, and strategic capital allocation plans, Henry Schein is poised for continued success and expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Announces Exclusive Distribution Agreement of Radic8 Air Purifier Systems in the U.S.

Henry Schein Announces Exclusive Distribution Agreement of Radic8 Air Purifier Systems in the U.S. and Canada

Henry Schein (HSIC) seems upbeat about its dental technology business, Henry Schein One.

Henry Schein Banks on Dental Consumable Amid Coronavirus Woes

Henry Schein's (HSIC) VisualDx system to be integrated with Medpod's technology infrastructure for improved patient outcome.

Henry Schein Medical to Expand in Telemedicine With VisualDx

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical professionals, today announced the successful completion of amendments and extensions of certain of its financing facilities, which enhances the Company’s liquidity and financial flexibility. Henry Schein amended and extended its existing $350 million facility with a bank, based on the securitization of its accounts receivable. The maturity

Henry Schein Amends and Extends Financing Facilities

AmerisourceBergen

Align Technology

Becton, Dickinson and Co.

Cardinal Health

Cooper Companies

Labcorp Holdings Inc

McKesson

Patterson Companies

DENTSPLY SIRONA

Near-Term Outlook Bleak for Medical Dental Supplies Industry

Henry Schein (HSIC) also seems to be upbeat about its dental technology business, Henry Schein One.

Henry Schein Dental Software Arm May Rebound Despite Pandemic

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

Why Is Henry Schein (HSIC) Up 20% Since Last Earnings Report?

Henry Schein (HSIC) registers dismal performance within Dental business on suspension of non-emergency procedures in response to the pandemic.

Henry Schein Sales Drop on Coronavirus Woes, Costs Rise

Henry Schein, Inc. (HSIC) CEO Stanley Bergman on Q1 2020 Results - Earnings Call Transcript

Henry Schein (HSIC) sees dismal performance by Dental arm in Q1 due to disruptions resulting from the coronavirus pandemic.

Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates

Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Henry Schein (HSIC) to Report a Decline in Earnings: What to Look Out for

Henry Schein: Upside As Demand For Dental Supplies Can Quickly Recover

Abbott Labs

Hologic

iShares U.S. Medical Devices ETF

iShares U.S. Healthcare ETF

QIAGEN

Thermo Fisher Scientific

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols,  resource allocation and drafting the right healthcare policies.

Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress

Henry Schein Inc. HSIC, -4.31% said it was withdrawing its financial guidance provided in February, citing the growing impact of the coronavirus pandemic on its business.

Henry Schein cuts executive pay, suspends stock buybacks and withdraws guidance

SPDR S&P Health Care Equipment ETF

A growing demand for COVID-19 tests has indulged major healthcare place in the race to develop competent testing kits.

Healthcare ETFs Gain on Rising Demand for COVID-19 Tests

Henry Schein (HSIC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Henry Schein (HSIC) Jumps: Stock Rises 7.1%

Henry Schein, Inc. (NASDAQ: HSIC) shares trading higher on Thursday, after the company announced the availability of its Standard Q coronavirus test.

Why Henry Schein's Stock Traded Higher Today

Why Is Henry Schein (HSIC) Down 34.7% Since Last Earnings Report?

Henry Schein (HSIC) strengthens position in Spain and Portugal by signing a JV with Casa Schmidt.

Henry Schein (HSIC) Expands by Signing JV With Casa Schmidt

Medtronic

As the coronavirus chaos continues to rise, MedTech firms have been witnessing a spike in demand for protective respiratory equipment.

3 MedTech Stocks to Rebound After Coronavirus-Led Recoil

Investor confidence continues to be high in Henry Schein (HSIC) stock, courtesy of solid prospects.

Here's Why You Should Retain Henry Schein (HSIC) Stock Now

Henry Schein, Inc. (HSIC) CEO Stanley Bergman on Q4 2019 Results - Earnings Call Transcript

A Relative Strength Rating upgrade for Henry Schein shows improving technical performance. Will it continue?

Henry Schein Showed Rising Relative Strength Prior To Earnings

Henry Schein (HSIC) delivered earnings and revenue surprises of 6.59% and 1.06%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Tops Q4 Earnings and Revenue Estimates

Consistent contribution from Henry Schein One is likely to have benefited Henry Schein's (HSIC) Q4 performance.

News for Henry Schein Stock (HSIC)